Clinical trial · Interventional

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Safety and Efficacy of SHR-A1811 Combine With Pyrotinib for the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer, a Phase II Study

NCT07132242CI-TRIAL-00093870not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy. Participants will take SHR-A1811 and pyrotinib every three weeks, until disease progression or intolerable toxicity.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Metastatic Breast Cancer With HER2 Positive	Breast Neoplasm	ONTOLOGY_EXACT	0.90

Interventions

Interventions (4)

Intervention	Type	Mapped drug	Match
Pyrotinib 240mg	Drug	Pyrotinib	ALIAS
Pyrotinib 320mg	Drug	Pyrotinib	ALIAS
SHR-A1811 4.0mg/kg	Drug	—	UNRESOLVED
SHR-A1811 4.8mg/kg	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (4)

type
EXPERIMENTAL
label
Arm 1：SHR-A1811 4.0mg/kg + Pyrotinib 240mg/Day
interventionNames
1. Drug: SHR-A1811 4.0mg/kg
2. Drug: Pyrotinib 240mg
type
EXPERIMENTAL
label
Arm 2：SHR-A1811 4.0mg/kg + Pyrotinib 320mg/Day
interventionNames
1. Drug: SHR-A1811 4.0mg/kg
2. Drug: Pyrotinib 320mg
type
EXPERIMENTAL
label
Arm 3: SHR-A1811 4.8mg/kg + Pyrotinib 240mg/Day
interventionNames
1. Drug: Pyrotinib 240mg
2. Drug: SHR-A1811 4.8mg/kg

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 70 Years

Show eligibility criteria text

Inclusion Criteria:

* Age: ≥18 years old and ≤70 years old;
* Pathologically confirmed HER2-positive locally advanced or metastatic breast cancer;
* Progression during or after prior HER2-targeted therapy and chemotherapy in the advanced/metastatic setting OR progression during/within 12 months after completion of trastuzumab and taxane-based chemotherapy in the neoadjuvant/adjuvant setting OR after 2 cycles of trastuzumab and taxane-based chemotherapy in the neoadjuvant setting with suboptimal response (assessed as non-response) for locally advanced disease;
* At least one measurable lesion per RECIST v1.1 criteria.
* ECOG performance status of 0 or 1.
* Adequate Organ Function
* Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose. Male subjects with partners of childbearing potential must be surgically sterile or agree to use effective contraception during the trial. Sperm donation is not permitted during the study period.
* Subjects must voluntarily enroll in this study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with follow-up.

Exclusion Criteria:

* Prior Pyrotinib in Advanced/Metastatic Setting;
* Prior Tropoisomerase I Inhibitor ADC Therapy;
* Active CNS Metastases;
* Other Malignancy;
* Recent Major Surgery/Trauma;
* Interstitial Lung Disease (ILD)/Severe Pulmonary Conditions;
* Significant Cardiac Disease;
* Inability to swallow oral medication, chronic diarrhea, intestinal obstruction, or other factors significantly affecting drug ingestion or absorption;
* Known hypersensitivity to any component of the investigational drugs in this study protocol;
* Immunodeficiency/Organ Transplant;
* Uncontrolled Third-Space Fluid Accumulation;
* Pregnancy/Breastfeeding/Contraception;
* Severe concomitant illness or comorbid conditions that may interfere with planned treatment or preclude study participation, as assessed by the investigator. This includes, but is not limited to, active hepatitis B or pulmonary infection requiring treatment.

References

Publications (0)

Data not yet available

No reference posted for this study.